BTK inhibition with rilzabrutinib was associated with a numerical decrease in LOAC events that was not statistically significant. However, continued meaningful asthma symptom improvements over 12 weeks were observed, despite background therapy withdrawal, potentially identifying a novel mechanism to treat uncontrolled symptomatic asthma.
The Lancet Respiratory Medicine published a clinical update in Critical Care on 02 Apr 2026. The item focuses on Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study. Open the detail page to review the full original feed content.